RT Journal Article SR Electronic T1 CanVasc consensus recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitis: 2020 update JF The Journal of Rheumatology JO J Rheumatol FD The Journal of Rheumatology SP jrheum.200721 DO 10.3899/jrheum.200721 A1 Mendel, Arielle A1 Ennis, Daniel A1 Go, Ellen A1 Bakowsky, Volodko A1 Baldwin, Corisande A1 Benseler, Susanne M. A1 Cabral, David A. A1 Carette, Simon A1 Clements-Baker, Marie A1 Clifford, Alison A1 Cohen Tervaert, Jan Willem A1 Cox, Gerard A1 Dehghan, Natasha A1 Dipchand, Christine A1 Dhindsa, Navjot A1 Famorca, Leilani A1 Fifi-Mah, Aurore A1 Garner, Stephanie A1 Girard, Louis-Philippe A1 Lessard, Clode A1 Liang, Patrick A1 Noone, Damien A1 Makhzoum, Jean-Paul A1 Milman, Nataliya A1 Pineau, Christian A. A1 Reich, Heather N. A1 Rhéaume, Maxime A1 Robinson, David B. A1 Rumsey, Dax G. A1 Towheed, Tanveer E. A1 Trudeau, Judith A1 Twilt, Marinka A1 Yacyshyn, Elaine A1 Yeung, Rae A1 Barra, Lillian A1 Khalidi, Nader A1 Pagnoux, Christian YR 2020 UL http://www.jrheum.org/content/early/2020/09/10/jrheum.200721.abstract AB Objective In 2015, the Canadian Vasculitis Research Network (CanVasc) created recommendations for the management of antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) in Canada. The current update aimed to revise existing recommendations and create additional recommendations, as needed, based on a review of new available evidence. Methods A needs assessment survey of CanVasc members informed questions for an updated systematic literature review (publications spanning May 2014-September 2019) using Medline, Embase, and Cochrane. New and revised recommendations were developed and categorized according to the level of evidence and strength of each recommendation. The CanVasc working group used a two-step modified Delphi procedure to reach >80% consensus on the inclusion, wording and grading of each new and revised recommendation. Results Eleven new and 16 revised recommendations were created, and 12 original (2015) recommendations were retained. New and revised recommendations are discussed in detail within this document. Five original recommendations were removed, of which 4 were incorporated into the explanatory text. The supplementary appendix for practical use was revised to reflect the updated recommendations. Conclusion The 2020 updated recommendations provide rheumatologists, nephrologists, and other specialists caring for patients with AAV in Canada with new management guidance, based on current evidence and consensus from Canadian experts.